Unibest

Pharmaceutical intermediates

Vericiguat Intermediates

2 pharmaceutical intermediates for Vericiguat. Indication: Heart Failure; Shock.

Submit a ProjectAll intermediates

About Vericiguat

Originator
Bayer
Indication
Heart Failure; Shock
Approved Date
01/19/2021
NCE Patent
01/19/2026
DS/DP
05/19/2031

Available intermediates

2 intermediates currently listed for Vericiguat. Request specifications, documentation or a quotation for any item below.

Vericiguat intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile1350653-26-7//
Phenylazomalononitrile6017-21-6//

Other programs under V

Valbenazine Tosylate (NBI-98854)Varenicline TartrateVelpatasvirVenetoclaxVibegronVilazodone HydrochlorideVONOPRAZAN FUMARATEVoxelotor

Building toward Vericiguat?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →